Hostname: page-component-848d4c4894-75dct Total loading time: 0 Render date: 2024-06-06T14:58:53.425Z Has data issue: false hasContentIssue false

Intermediate- and long-term follow-up of device closure of patent arterial duct with severe pulmonary hypertension: factors predicting outcome

Published online by Cambridge University Press:  02 May 2016

Masood Sadiq*
Affiliation:
The Children’s Hospital, Punjab Institute of Cardiology, Lahore, Pakistan
Asif U. Rehman
Affiliation:
The Children’s Hospital, Punjab Institute of Cardiology, Lahore, Pakistan
Najam Hyder
Affiliation:
The Children’s Hospital, Punjab Institute of Cardiology, Lahore, Pakistan
Ahmad U. Qureshi
Affiliation:
The Children’s Hospital, Punjab Institute of Cardiology, Lahore, Pakistan
Tehmina Kazmi
Affiliation:
The Children’s Hospital, Punjab Institute of Cardiology, Lahore, Pakistan
Shakeel A. Qureshi
Affiliation:
Evelina London Children’s Hospital, Guy’s and St Thomas’ Trust, London, United Kingdom
*
Correspondence to: Dr M. Sadiq, FRCP, The Children’s Hospital, Punjab Institute of Cardiology, Lahore 5600, Pakistan. Tel: + 0092 42 99231723; Fax: +0092 42 99230358; E-mail: drmasoodsadiq@hotmail.com

Abstract

Background

In patients with large patent arterial ducts and severe pulmonary hypertension, the natural history of progression of pulmonary hypertension is very variable. Whether to close or not to close is often a difficult decision, as there are no established haemodynamic parameters predicting reversibility.

Objectives

The objectives of this study were to evaluate the results of device closure of large patent arterial ducts with severe pulmonary hypertension after 2 years of age and to determine haemodynamic variables associated with its regression during long-term follow-up.

Methods

A total of 45 patients, with median age of 10 (2–27) years, with large patent arterial ducts and severe pulmonary hypertension, were considered. Haemodynamic variables were assessed in air, oxygen, and after occlusion. The follow-up was performed to assess regression of pulmonary hypertension.

Results

Device closure was successful in 43 (96%) patients. Pulmonary artery systolic and mean pressures decreased from 79 to 67 mmHg and from 59 to 50 mmHg, respectively (p<0.001). At a median follow-up of 80 (41–151) months, severe pulmonary hypertension persisted in four (9.7%) patients. Multivariate analysis showed pulmonary vascular resistance index ⩽6 WU m2 and pulmonary artery systolic and mean pressures ⩽75 and ⩽55 mmHg (all in oxygen), having 97.8% predictive value for regression of pulmonary hypertension (p<0.001) in the long term. In 24 patients with catheterisation-based criteria, regression of pulmonary hypertension was associated with pulmonary vascular resistance index <8 WU m2 (p=0.001) and its fall of >25% (both in oxygen) (p=0.007).

Conclusions

Device closure of large patent arterial ducts with severe pulmonary hypertension is safe and effective. Pulmonary vascular resistance index and systolic and mean pulmonary artery pressures in oxygen are the key prognostic variables predicting regression of pulmonary hypertension.

Type
Original Articles
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Butrous, G, Ghofrani, HA, Grimminger, F. Pulmonary vascular disease in the developing world. Circulation 2008; 118: 17581766.Google Scholar
2. Campbell, M. Natural history of persistent ductus arteriosus. Br Heart J 1968; 30: 413.Google Scholar
3. Yu, ML, Huang, XM, Wang, JF, et al. Safety and efficacy of transcatheter closure of large patent ductus arteriosus in adults with a self-expandable occluder. Heart Vessels 2009; 24: 440445.Google Scholar
4. Viswanathan, S, Kumar, K. Assessment of operability of congenital cardiac shunts with increased pulmonary vascular resistance. Catheter Cardiovasc Interv 2008; 71: 665670.Google Scholar
5. Roy, A, Juneja, R, Saxena, A. Use of Amplatzer duct occluder to close severely hypertensive ducts: utility of transient balloon occlusion. Indian Heart J 2005; 57: 332336.Google ScholarPubMed
6. Thanopoulos, BD, Tsaousis, GS, Djukic, M, Hakim, FA, Eleftheraskis, NG, Simeunovic, SD. Transcatheter closure of high pulmonary artery pressure patent ductus arteriosus with Amplatzer muscular ventricular septal occluder. Heart 2002; 87: 260263.Google Scholar
7. Qiang, JI, Feng, J, Mei, Y, et al. Transcatheter closure of adult patent ductus arteriosus with severe pulmonary hypertension. Hypertens Res 2008; 31: 19972002.Google Scholar
8. Yan, C, Zhao, S, Jiang, S, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart 2007; 93: 514518.Google Scholar
9. Lee, CH, Leung, YL, Kwong, NP, Kwok, OH, Yip, AS, Chow, WH. Transcatheter closure of patent ductus arteriosus in Chinese adult: immediate and long term results. J Invasive Cardiol 2003; 15: 2630.Google Scholar
10. Zabal, C, García-Montes, JA, Buendía-Hernández, A, et al. Percutaneous closure of hypertensive ductus arteriosus. Heart 2010; 96: 625629.Google Scholar
11. Sadiq, M, Akram, Z, Butt, M, Sheikh, SA. Transcatheter occlusion of moderate and large size patent arterial duct using Amplatzer device – immediate and intermediate term results. Pak J Cardiol 2000; 11: 105110.Google Scholar
12. Rigby, ML. Closure of a large patent ductus arteriosus in adults: first do no harm. Heart 2007; 93: 417418.Google Scholar
13. Rudski, LG, Lai, WW, Afilalo, J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr 2010; 23: 685713.Google Scholar
14. Krichenko, A, Benson, LN, Burrows, P, Moes, CA, McLaughlin, P, Freedon, RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol 1989; 63: 877880.Google Scholar
15. Toda, R, Moriyama, Y, Yamashita, M, Iguro, Y, Matsumoto, H, Yotsumoto, G. Operation for adult patent ductus arteriosus using cardiopulmonary bypass. Ann Thorac Surg 2000; 70: 19351938.Google Scholar
16. Taira, A, Akita, H. Patch closure of the ductus arteriosus: an improved method. Ann Thorac Surg 1976; 21: 454455.Google Scholar
17. Atiq, M, Aslam, N, Kazmi, KA. Transcatheter closure of small to large patent ductus arteriosus with different devices: queries and challenges. J Invasive Cardiol 2007; 19: 295298.Google Scholar
18. Giroud, JM, Jacobs, JP. Evolution of strategies for management of patent arterial duct. Cardiol Young 2007; 17: 6874.Google Scholar
19. Rabinovitch, M, Haworth, SG, Castaneda, AR, Nadas, AS, Reid, LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978; 58: 11071122.Google Scholar
20. Haworth, SG. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 1987; 152: 157168.Google Scholar
21. Bush, A, Bust, CM, Haworth, SG, et al. Correlation of lung morphology, pulmonary vascular resistance and outcome in children with congenital heart disease. Br Heart J 1988; 59: 480484.Google Scholar
22. Moller, JH, Patton, C, Varco, RL, Lillehei, CW. Late results (30 to 35 years) after operative closure of isolated ventricular septal defect from 1954 to 1960. Am J Cardiol 1991; 68: 14911497.Google Scholar
23. Kannan, BR, Sivasankaran, S, Tharakan, JA, et al. Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Indian Heart J 2003; 55: 161166.Google ScholarPubMed
24. Galie, N, Beghetti, M, Gatzoulis, MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 4854.Google Scholar
25. Maiya, S, Hislop, AA, Flynn, Y, Haworth, SG. Response to Bosentan in children with pulmonary hypertension. Heart 2006; 92: 664670.Google Scholar
26. Singh, TP, Rohit, M, Grover, A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: e1e5.Google Scholar
27. Humpl, T, Reyes, JT, Holtby, H, Stephens, D, Adatia, I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005; 111: 32743280.Google Scholar
28. Wilkinson, JL. Haemodynamic calculations in the catheter laboratory. Heart 2001; 85: 113120.Google Scholar
29. Rutledge, J, Bush, A, Shekerdemian, L, et al. Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years – a revisit. Am Heart J 2010; 160: 109114.Google Scholar
30. McLaughlin, VV, Archer, SL, Badesch, DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53 (17): 15731619.Google Scholar
31. Groh, GK, Levy, PT, Holland, MR, et al. Doppler echocardiography inaccurately estimates right ventricular pressure in children with elevated right heart pressure. J Am Soc Echocardiogr 2014; 27: 163171.Google Scholar